Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 1Phase 2 Interventional Results available

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

NCT02643862
View directory record Official record
Conditions
Food Allergy
Interventions
Xolair, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 28, 2026, 3:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.

NCT00339703
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 28, 2026, 3:40 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

NCT07564141
View directory record Official record
Conditions
Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Interventions
Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel, PLD
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Duarte, California • Danbury, Connecticut • Tigard, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Omalizumab to Treat Eosinophilic Gastroenteritis

NCT00084097
View directory record Official record
Conditions
Gastroenteritis
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 76 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 3:40 AM EDT
Not listed No phase listed Observational

Patient Reported Outcome Instruments in Sarcoidosis

NCT04342403
View directory record Official record
Conditions
Sarcoidosis
Interventions
Quality of Life
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 28, 2026, 3:40 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

NCT05399368
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 28, 2026, 3:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 17 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Northbrook, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Terminated Not applicable Interventional

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

NCT03016156
View directory record Official record
Conditions
Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions
CRADLE, Red reflex testing
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 7 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

NCT00108446
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
dextromethorphan, naloxone, fentanyl, lidocaine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 28, 2026, 3:40 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT05911841
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Fort Smith, Arkansas • North Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 28, 2026, 3:40 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional Results available

Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes

NCT04878120
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Standard HCL System, HCL System with Smart Bolus Calculator
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional

Home Visits to Optimize Medical and Educational Success Among Sacramento Schoolchildren With Asthma

NCT03335046
View directory record Official record
Conditions
Asthma, Chronic School Absenteeism
Interventions
Home Visit, Standard Care
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
5 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 28, 2026, 3:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Differences in Airway Inflammation in Asthma

NCT00584441
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional

Remote Physician Care for Home Hospital Patients

NCT04080570
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Remote Visit
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 28, 2026, 3:40 AM EDT
Terminated Phase 1 Interventional

Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

NCT00517582
View directory record Official record
Conditions
Angioneurotic Edema
Interventions
HOE-140, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

NCT00043082
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
carboplatin, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional

Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits

NCT04159168
View directory record Official record
Conditions
Affective Symptoms, Empathy
Interventions
Facial Affect Sensitivity Training (FAST), Implicit Gaze Training task (Active control condition)
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
6 Years to 11 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 1 Interventional Results available

Validation of the Short-term Antimicrobial Action of Transplanted Bacteria

NCT01959113
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Autologous Microbiome Transplant, Placebo Arm
Biological · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

NCT04504279
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB-401, Placebo
Biological
Lead sponsor
Forte Biosciences, Inc.
Industry
Eligibility
2 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Fremont, California • Lake City, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 28, 2026, 3:40 AM EDT